Top-News

IMMUNICUM AB News

Aktie
WKN:  A1W59F ISIN:  SE0005003654
0,0354 €
+0,00 €
0,00%
19:13:01 Uhr
Handeln Depot/Watchlist
Aktienanzahl *
-
Marktkapitalisierung *
-
Streubesitz
-
Index-Zugehörigkeit
-

IMMUNICUM AB News

01.09.22 - GlobeNewswire
Mendus AB: Mendus to participate in upcoming conferences in September
Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on improving survival outcomes for cancer patients with tumor recurrence through cell-​based ...
14.07.22 - GlobeNewswire
Mendus AB: Mendus Publishes Preclinical Data Demonstrating Significant Anti-Tumor Synergies of Intratumoral Immune Priming with CTLA-4 Inhibition
Intratumoral injection of allogeneic pro-​inflammatory dendritic cells (“ilixadencel”) substantially and sustainably enhanced an otherwise ineffective systemic anti CTLA-4 treatment in ...
23.06.22 - GlobeNewswire
Immunicum AB: Immunicum Announces Corporate Rebranding and Name Change to Mendus AB
Rebranding reflects advancing pipeline in next generation cancer immunotherapies, upcoming manufacturing expansion, and long-term corporate aspirations The Company’s stock ...
09.06.22 - GlobeNewswire
Immunicum AB: Immunicum Received FDA Orphan Drug Designation for Ilixadencel as Treatment of Gastrointestinal Stromal Tumors (GIST)
Immunicum AB (“Immunicum” publ; IMMU.ST), a biopharmaceutical company focused on tumor recurrence and hard-​to-treat established tumors, announced today that it has been ...
01.06.22 - GlobeNewswire
Immunicum AB: Immunicum to Participate in Upcoming Conferences
Immunicum AB (publ; IMMU.ST), a biopharmaceutical company focused on therapies addressing tumor recurrence and hard-​to-treat established tumors, today announced its ...
16.05.22 - GlobeNewswire
Immunicum AB: Immunicum Announces Positive Interim Results from ADVANCE II Study in AML Maintenance Treatment
Analysis of primary study endpoint was completed with 7 patients showing a measurable residual disease (MRD) response, of which 5 patients converted from MRD+ to MRD- and ...
10.05.22 - GlobeNewswire
Immunicum AB: Immunicum AB (publ) Interim Report January – March 2022
JANUARY - MARCH IN SUMMARY Net sales for the period amounted to KSEK 1,794 (–). Result for the period amounted to KSEK -27,582 (-41,571). Earnings and diluted earnings ...
05.05.22 - GlobeNewswire
Immunicum AB: Immunicum Appoints Leopold Bertea as Chief Technology Officer
Immunicum AB (“Immunicum” publ; IMMU.ST), a biopharmaceutical company focused on therapies addressing tumor recurrence and hard-​to-treat established tumors, announced ...
03.05.22 - GlobeNewswire
Immunicum AB: Immunicum to Present Preclinical Data Demonstrating Synergy of DCP-001 with Standard Treatments for Acute Myeloid Leukemia
COMBINA TION OF CANCER RELAPSE VACCINE CANDIDATE WITH 5’-AZACITIDINE AND VENETOCLAX SHOWS SUPERIOR TUMOR REDUCTION IN AN AML MODEL Immunicum ...
28.04.22 - GlobeNewswire
Immunicum AB: Immunicum Publishes Phase II MERECA Trial Results of Ilixadencel in Kidney Cancer in European Urology Open Sciences
Immunicum AB (“Immunicum” publ; IMMU.ST), a biopharmaceutical company focused on therapies addressing tumor recurrence and hard-​to-treat established tumors, has ...
19.04.22 - GlobeNewswire
Immunicum AB: Immunicum to Participate in Upcoming Conferences
Immunicum AB (publ; IMMU.ST), a biopharmaceutical company focused on therapies addressing tumor recurrence and hard-​to-treat established tumors, today announced its ...
15.04.22 - GlobeNewswire
Immunicum AB: Immunicum AB (publ) Publishes the Annual Report for 2021
Immunicum AB (“Immunicum” publ; IMMU.ST), a biopharmaceutical company focused on therapies addressing tumor recurrence and hard-​to-treat established tumors, today ...
14.04.22 - GlobeNewswire
Immunicum AB: Immunicum to Participate in the New Cancer Research Consortium Oncode-PACT
Immunicum AB (“Immunicum” publ; IMMU.ST), a biopharmaceutical company focused on therapies addressing tumor recurrence and hard-​to-treat established tumors, today ...
08.04.22 - GlobeNewswire
Immunicum AB: Notice of Annual General Meeting in Immunicum AB (publ)
Press Release
07.03.22 - GlobeNewswire
Immunicum AB: Invitation to Immunicum's Investor Event in Gothenburg on March 14, 2022
Immunicum AB (“Immunicum” publ; IMMU.ST), a biopharmaceutical company focused on tumor recurrence and hard-​to-treat established tumors, today announced that on Monday, 14 ...
18.02.22 - GlobeNewswire
Correction: Immunicum AB: Immunicum AB (publ) Announces Q4 and Year-End Results 2021
Correction: Immunicum AB: Immunicum AB (publ) Announces Q4 and Year-End Results 2021
10.02.22 - GlobeNewswire
Immunicum AB: Invitation to Immunicum's Full-Year 2021 Review and Pipeline and Strategy Outlook Held as a Hybrid Event on February 17, 2022
Immunicum AB (“Immunicum” publ; IMMU.ST), a biopharmaceutical company focused on the prevention of cancer recurrence and addressing hard-​to-treat tumors, will publish its ...
03.01.22 - GlobeNewswire
Immunicum to Participate in Upcoming Investor and Industry Conferences in January
Press Release Stockholm, Sweden, January 3, 2022 Immunicum to Participate in Upcoming Investor and Industry Conferences in January Immunicum AB (“Immunicum” publ; ...
21.12.21 - GlobeNewswire
Immunicum Publishes Year-End Letter by CEO and Announces Upcoming Shareholder Event to Present Pipeline Outlook
Press Release
22.11.21 - GlobeNewswire
Immunicum Publishes DCP-001 Mechanism of Action in the Journal Cells
Press Release Stockholm, Sweden, November 22, 2021 Immunicum Publishes DCP-001 Mechanism of Action in the Journal Cells Immunicum AB (publ; IMMU.ST), a ...

Newssuche

Videos

17.05.24 +2,11%
Technical Trading: Gold Long-​Chance
Gold Long Typ: Turbo Open End WKN: VD1G7Y Hebel: 10 Laufzeit: OpenEnd Einstieg: Market ... Mehr »